DORVAL, QC, May 8, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Timothy Maloney has been appointed Country Head and President, effective April 1, 2014. Mr. Maloney brings with him 28 years of pharmaceutical industry experience in both primary care and specialty product markets.
Since joining Novartis in 2003, he has held various positions of increasing responsibility in the United States and Global commercial organizations. After leading the U.S. cardiovascular business, he moved to Switzerland to lead the $7-billion Global Cardiovascular and Metabolism franchise. In 2011, Mr. Maloney successfully launched the company's Primary Care Franchise, contributing to the success of treatments for diabetes and hypertension, as well as building a world-class portfolio of products for respiratory diseases.
Mr. Maloney will also immediately start contributing to the overall Canadian research-based pharmaceutical industry by his appointment to the Board of Directors of Rx&D, Canada's Research-Based Pharmaceutical Companies.
Prior to joining Novartis, Mr. Maloney held sales and marketing leadership positions with Pfizer and its predecessor companies, Upjohn and Pharmacia. He holds a Bachelor of Science (BSc) in biology from the State University of New York (SUNY) at Plattsburgh, NY. He and his family will be relocating to Montreal from Basel, Switzerland.
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2012, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult www.novartis.ca.
Novartis Pharmaceuticals Canada Inc. is a subsidiary of Novartis AG which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis Group of Companies offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.
Image with caption: "Timothy Maloney, Country Head and President, Novartis Pharmaceuticals Canada Inc. (CNW Group/Novartis Pharmaceuticals Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20140508_C6673_PHOTO_EN_39973.jpg
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Novartis Media Relations
Novartis Pharmaceuticals Canada Inc.
+1 514 633-7873